USP <800> and the NIOSH hazardous-drug definition, the three HD types, routes of exposure, safety data sheets and what a technician is actually required to do.
USP General Chapter <800> — Hazardous Drugs
USP General Chapter <800> sets the operational standard for how healthcare sites receive, store, prepare, transport, administer, and clean up hazardous drugs. Whether <800> carries the force of law depends on state adoption, accreditation requirements, and employer policy — but in practice, most sites treat it as baseline.
The protection rules in USP <800> extend well beyond pharmacists and pharmacy technicians. Nurses, physicians, physician assistants, home-care staff, and veterinary personnel are all expected to work under USP <800> when they may touch a hazardous drug or contaminated waste. Anyone handling hazardous drugs must complete role-appropriate training and demonstrate continued competency on a scheduled basis.
Exam Tip: The PTCE tests USP <800> by number. Memorize the chapter number (<800>), and keep it distinct from <795> (nonsterile compounding) and <797> (sterile compounding).
NIOSH Hazardous-Drug Definition
NIOSH classifies a medication as hazardous when evidence in humans or animals shows at least one of six recognized hazard characteristics:
Carcinogenicity — can cause cancer.
Teratogenicity or other developmental toxicity — can cause birth defects.
Reproductive toxicity — can impair fertility or damage reproductive function.
Organ toxicity at low doses — damage at low exposure levels.
Genotoxicity — DNA or chromosomal damage.
Structural or toxicologic similarity to existing hazardous drugs — new agents resembling classified hazardous agents may be handled as hazardous pending review.
NIOSH Tables 1 and 2
The December 2024 NIOSH hazardous-drug list separates agents into two groups based on the strength of carcinogenicity evidence and the availability of manufacturer safe-handling guidance.
Comparison Point
Table 1
Table 2
Safe-handling information
Manufacturer guidance available, or otherwise meets the NIOSH definition
Meets the NIOSH definition but lacks manufacturer safe-handling guidance
National Toxicology Program status
Listed as a known human carcinogen
Not listed as a known human carcinogen
IARC status
Group 1 or Group 2A
Not in Group 1 or Group 2A
Practical handling
Treated as the higher-carcinogenicity group
Still hazardous, with less direct carcinogen classification support
The 2024 update also adds selected drugs to the hazardous list based on developmental or reproductive toxicity alone — confirming that hazardous handling is not limited to carcinogens.
Three HD Types under USP <800>
USP <800> groups hazardous drugs into three categories:
Antineoplastic — cancer-fighting agents such as chemotherapy drugs.
Nonantineoplastic — hazardous but not used for cancer treatment.
Reproductive risk only — primary risk is to reproductive health.
Common Trap: The PTCE sometimes pairs a non-chemotherapy hazardous drug with a distractor set that looks antineoplastic-only. Warfarin, estradiol, ethinyl estradiol/levonorgestrel, oxcarbazepine, and colchicine are all hazardous under NIOSH, and none are chemotherapy agents. Do not limit "hazardous drug" to oncology.
Safety Data Sheets (SDS) — OSHA Hazard Communication
Each hazardous chemical used in the pharmacy must have an available Safety Data Sheet. Manufacturers, distributors, and importers are legally responsible for supplying the SDS, and OSHA requires that SDSs remain readily accessible to workers handling hazardous chemicals.
An SDS summarizes:
Basic chemical properties.
Physical, health, and environmental risks.
Recommended protective measures.
Safe practices for handling, storage, and transport.
Reference the SDS:
Before handling, storing, or transporting a hazardous substance.
Whenever a spill or exposure occurs.
Any time questions arise about the chemical's hazards.
Definition: A Safety Data Sheet is the required document for each hazardous chemical that summarizes hazards, protective measures, and handling, storage, and transport precautions.
Routes of Hazardous-Drug Exposure
Exposure can happen at every stage of the drug's trip through the pharmacy:
Receiving: residue may already be on cartons, vials, unit-dose packaging, shelving, or floors.
Dispensing: counting, repackaging, and handling contaminated packaging can spread residue.
Compounding or manipulation: crushing, splitting, reconstituting, drawing up injectables, and cleaning contaminated equipment can all release particles.
Administration: aerosols, tubing priming, and certain specialized procedures expose staff.
Patient care: body fluids, contaminated clothing, linens, and dressings may carry hazardous residue.
Spill response, transport, and waste handling: each step risks new contamination if procedures fail.
Risk Assessment Factors (USP <800>)
A USP <800> risk assessment accounts for all of the following:
The type of hazardous drug (antineoplastic, nonantineoplastic, reproductive-risk only).
Its dosage form.
The likelihood that staff will be exposed during handling.
Whether the package stays intact or must be manipulated before use.
Engineering Controls
Primary Engineering Controls (C-PECs) for Sterile Hazardous Compounding
A C-PEC (Containment Primary Engineering Control) is the containment workstation where hazardous sterile compounding happens. It protects the preparer and the product simultaneously.
A biological safety cabinet (BSC) is one C-PEC type. For hazardous sterile work, the C-PEC is a Class II BSC — most commonly Type A2 (Type B2 is used for volatile hazardous drugs) — externally vented.
A CACI (compounding aseptic containment isolator) is the other common C-PEC. It is a closed isolator accessed through attached flexible glove sleeves or gauntlets. Supplies enter through a pass-through chamber sealable from both the main chamber and outside environment.
All materials placed in the pass-through must be wiped down with disinfectant first. The pass-through must be sealed and pressurized to match the compounding chamber before materials can be retrieved.
Every C-PEC used for hazardous sterile compounding must be externally vented to remove airborne hazardous particles.
C-PECs must operate continuously, even when compounding is not in progress.
C-PECs must be inspected and certified by qualified personnel every 6 months.
Exam Tip: The C-PEC for hazardous sterile work is a Class II BSC (commonly Type A2; Type B2 for volatile drugs) or a CACI, externally vented. The trap answer is a horizontal laminar-airflow workbench (no personnel containment at all) or a Class II Type A1 cabinet — a containment device, but with only 75 ft/min minimum inflow against a Type A2's 100 ft/min, so not acceptable for hazardous drugs.
Closed-System Transfer Devices (CSTDs)
A CSTD is a vial transfer system designed so hazardous drugs cannot be vented or exposed to the surrounding environment during compounding. Internal vial pressure during hazardous-drug reconstitution can create spills, aerosols, and surface contamination; the CSTD blocks that pathway. USP <800> and common practice call for CSTD use during hazardous-drug compounding whenever the dosage form allows it.
Definition (plain-language): A CSTD seals the path between the vial and the syringe so no hazardous aerosol, vapor, or liquid escapes during transfer.
Air Quality Requirements (USP <800>)
Space
Pressure
Minimum ACPH
ISO Classification
C-PEC (BSC or CACI)
Negative
Maintained by HEPA
ISO Class 5
Buffer room (C-SEC)
Negative relative to adjacent areas
30 ACPH
ISO Class 7
C-SCA (Containment Segregated Compounding Area)
Negative
12 ACPH
Not ISO-classified
Anteroom adjacent to negative buffer
Positive
30 ACPH
ISO Class 7
Exam numbers to memorize: The required pressure differential for a C-SEC is −0.01 to −0.03 inches of water column relative to adjacent areas. Buffer rooms maintain at least 30 ACPH and ISO Class 7. C-SCAs maintain at least 12 ACPH and must be externally vented.
Mnemonic: "30 / 30 / 12 ACPH" — Buffer (negative) = 30, Anteroom = 30, C-SCA = 12. Pair with "0.01 to 0.03 — Negative C-SEC" and "Ozone Outside (Externally Vented, Every 6 Months)." See the Mnemonic Library cheat sheet Section 6.
A C-SCA is not interchangeable with a full cleanroom suite. Under USP <797>, a Containment Segregated Compounding Area supports only Category 1 compounded sterile preparations (the shortest-BUD category). Category 2 and Category 3 CSPs require a full ISO Class 7 cleanroom suite — a C-SEC buffer room with its accompanying anteroom. A site that needs the longer beyond-use dating of Category 2 or 3 cannot rely on a C-SCA.
Negative-Pressure Storage
Antineoplastic hazardous drugs received outside protective final packaging must move quickly into the designated negative-pressure HD storage area, not sit with routine inventory.
Hazardous waste belongs only in approved hazardous-waste containers located in the appropriate negative-pressure area.
Personal Protective Equipment (PPE)
Technique matters most, but PPE is a core protective layer for anyone handling or preparing hazardous drugs. USP <800> requires PPE for compounding, administering, cleaning, and disposing of hazardous-drug waste.
Full PPE List
Gloves: two pairs of chemotherapy-tested gloves meeting ASTM D6978.
Gown: impermeable, back-closing, long-sleeved, with tight-fitting cuffs.
Shoe covers: as required by the task or area.
Head and hair covers: required in hazardous compounding areas.
Eye/face protection: used when splash risk exists.
Respirator: required when aerosol generation or spill cleanup creates inhalation risk.
Gown Requirements (Detail)
Validated as impermeable to liquid spills and splashes.
Solid front.
Made of lint-free material.
Long sleeves with tight-fitting elastic or knit cuffs.
Kept inside the hazardous-drug area — do not wear into clean or public spaces.
Changed immediately if contaminated.
Glove Protocol
Hazardous-drug work requires chemotherapy-rated gloves meeting ASTM D6978.
Wash hands before gloving and again after glove removal.
For all cytotoxic and hazardous substance procedures, two pairs of gloves are required, and the outer pair must be sterile when sterile compounding is underway. Double gloving applies whenever antineoplastics or other cytotoxic agents are prepared in a sterile environment.
Replace any glove that is torn, punctured, or visibly contaminated immediately.
Touch the outside of hazardous-waste containers only with gloves that have not been contaminated by the task.
Double-Gloving Technique
First (inner) pair goes under the gown cuff.
Second (outer) pair goes over the gown cuff.
This creates a continuous sealed barrier between skin and hazardous-drug residue.
Eyewash and First Aid
Hazardous-drug work areas require nearby eyewash and first-aid access.
For skin or eye contact, begin the facility's first-aid steps immediately, obtain prompt medical evaluation, and document the exposure per policy.
OSHA 15-minute rule: when a hazardous chemical or drug contacts the eye, irrigate the eye at an eyewash fountain or with water or isotonic eyewash solution for at least 15 minutes. The 15-minute duration is the testable number.
OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030)
The OSHA Bloodborne Pathogens Standard protects pharmacy and healthcare employees from occupational exposure to blood and other potentially infectious materials.
Training is required at initial assignment and at least annually thereafter.
Training must be offered at no cost to the employee during working hours.
Program elements include exposure-control plans, engineering and work-practice controls, PPE, Hepatitis B vaccination offered within 10 working days of assignment, sharps-injury logs, and post-exposure evaluation and follow-up.
Common Trap: OSHA bloodborne pathogens training is annual (every year). DEA controlled-substance inventory is biennial (every 2 years). Watch for a distractor that swaps these two.
Common Traps
Here's where people miss it on Section 2.1. The chapter scatters these warnings inline as you read; this section pulls them together so they are easy to drill before the exam.
Limiting "hazardous drug" to oncology. Hazardous drugs are not only chemotherapy agents. Warfarin, estradiol, ethinyl estradiol/levonorgestrel, oxcarbazepine, and colchicine are all hazardous under NIOSH and none are antineoplastics. USP <800> recognizes three categories — antineoplastic, nonantineoplastic, and reproductive-risk only.
Swapping the OSHA-annual and DEA-biennial intervals. OSHA bloodborne-pathogens training is annual (every year). DEA controlled-substance inventory is biennial (every 2 years). The exam writes this swap as a classic distractor.
Treating "hazardous drug" and "hazardous waste" as one category. "Hazardous drug" is a NIOSH / USP <800> classification; "hazardous waste" is an EPA / RCRA classification. A drug can be one, the other, or both. Check both frameworks — the disposal answer depends on the EPA code, not the handling category.
Missing the warfarin P-list / U-list split. Warfarin waste is concentration-dependent. Commercial chemical products with more than 0.3% warfarin are P001 acute hazardous waste; warfarin at 0.3% or less is U248 hazardous waste. Know both codes.
Answering with the wrong C-PEC. Hazardous sterile compounding requires a Class II BSC (most commonly Type A2; Type B2 for volatile drugs) or a CACI, externally vented. A horizontal laminar-airflow workbench provides no personnel containment at all, and a Class II Type A1 cabinet, though a real containment device, is not acceptable for hazardous drugs — its minimum inflow velocity is only 75 ft/min, against the 100 ft/min a Type A2 provides. Both are wrong answers.
Confusing the USP chapter numbers. <800> is hazardous drugs, <797> is sterile compounding, <795> is nonsterile compounding. The exam tests <800> by number.
Confusing NIOSH with OSHA.NIOSH researches and classifies hazards (it is part of the CDC and is not a regulatory agency). OSHA is the regulatory and enforcement arm for workplace safety.
Missing the certification interval. C-PECs are inspected and certified every 6 months — not annually — and must operate continuously even when compounding is not in progress.
Forgetting the eyewash duration. After a hazardous chemical or drug contacts the eye, the OSHA rule is irrigation for at least 15 minutes. The 15-minute number is the testable fact.
Overlooking patient-care exposure. The most overlooked route of hazardous-drug exposure is patient care — body fluids, contaminated linens, dressings, and clothing can all carry hazardous residue.
Skipping the pharmacist on a spill. Any hazardous-drug spill is a pharmacist-notification event, even when the technician performs the cleanup. The PIC's visibility starts at discovery, not at the end of containment.
Mishandling the post-needlestick sequence. After a needlestick the worker washes with soap and water first, then reports to the supervisor; paperwork and infection-control notification follow the first-aid action.
Quick Review Checklist
A fast scan of the highest-yield Section 2.1 facts. If any line does not land, go back to the matching body section before moving on.
Six NIOSH hazard characteristics — carcinogenicity, teratogenicity/developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, structural/toxicologic similarity to existing hazardous drugs.
Three USP <800> HD categories — antineoplastic, nonantineoplastic, reproductive-risk only.
C-PEC for hazardous sterile work — Class II BSC (most commonly Type A2; Type B2 for volatile drugs) or a CACI with pass-through chamber; externally vented; continuous operation; certified every 6 months.
Air quality — C-PEC interior ISO Class 5; buffer room (C-SEC) ISO Class 7, 30 ACPH, negative; C-SCA 12 ACPH, externally vented, not ISO-classified; anteroom ISO Class 7, 30 ACPH, positive.
C-SEC pressure differential — −0.01 to −0.03 inches of water column relative to adjacent areas.
CSTD — closed-system transfer device; prevents hazardous vapor, aerosol, or liquid escape during transfer.
Gloves — chemotherapy-tested, ASTM D6978; double-glove (inner pair under the gown cuff, outer pair over); the outer pair is sterile for cytotoxic sterile compounding.
OSHA eyewash — irrigate the eye for at least 15 minutes after chemical/drug eye contact.
OSHA bloodborne pathogens (29 CFR 1910.1030) — training at initial assignment and annually; Hepatitis B vaccine offered within 10 working days of assignment.
DEA controlled-substance inventory — biennial (every 2 years) — do not swap with the annual OSHA training interval.
Free Top 200 drugs sheet. Brand, generic, class,
all the controlled-substance schedules on one page, and the look-alike pairs — built by a
pharmacist who precepts technicians. No signup gate on the content itself.
Get the free sheet.